Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

The role of PMNs and CD73 in host-resistance against S. pneumoniae / influenza A virus co-infection

Award Number: R21AI167956
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/24/2023
PERIOD OF PERFORMANCE END DATE: 01/31/2026

Group Awards By:

View Award Description

The role of PMNs and CD73 in host-resistance against S. pneumoniae / influenza A virus co-infection - ABSTRACT Following influenza A virus (IAV) infection, the risk for subsequent pneumococcal pneumonia caused by Streptococcus pneumoniae is enhanced 100-fold. Host aging is associated with more severe outcomes, thus novel approaches that boost resistance to infections are needed. Our goal is to elucidate how IAV infection alters the responses of polymorphonuclear leukocytes (PMN) and the extracellular adenosine (EAD) pathway across host age, during pneumococcal pneumonia. Background: Following primary S. pneumoniae infection, PMNs, which are innate immune cells whose function declines with age, are required for controlling bacterial numbers. EAD, which is produced from breakdown of ATP leaking from injured cells by CD73, controls PMN responses during infection. We found that CD73 was crucial for host resistance and PMN pulmonary influx as well as anti-microbial function during primary pneumococcal pneumonia. Importantly, old mice had significant changes in expression of EAD enzymes and receptors and targeting this pathway reversed the age-driven susceptibility to primary pneumococcal infection. In humans, pneumococcal carriage in the nasopharynx is a prerequisite to invasive diseases. Further, IAV infection of the respiratory tract where it triggers epithelial damage and impairs host antibacterial responses is key for the lethal synergy of co-infection. However, animal models incorporating the evolution of S. pneumoniae from colonizer to pathogen during IAV co-infection while mimicking the severe disease seen in humans, are lacking. Therefore, we established an optimized model where mice are intra-nasally colonized with pneumococci followed by IAV infection of the nasopharynx and lungs. This model resulted in obvious signs of illness and lethality in half of the young mice and importantly, reproduced the susceptibility of aging, where significantly more old mice displayed severe clinical signs and succumbed to lethality compared to young controls. Using this model, we strikingly found that the role of CD73 was reversed, where CD73 became detrimental to resistance of young hosts to co-infection. This highlighted that IAV infection triggers profound changes in the interaction of the host with pneumococci. However, the effect of polymicrobial infections on host responses and the mechanisms behind that remain a gap in the field. Here we will use our improved model to test the Hypothesis that IAV infection alters CD73-mediated control of PMN responses to pneumococcal infection across host age using two specific Aims: 1) Test the effect of age and IAV infection on PMN responses during secondary pneumococcal pneumonia; 2) Test the role of CD73 in PMN responses and host resistance to S. pneumoniae/IAV co-infection. Significance/innovation/ relevance: Using this physiologically relevant model that mimics aspects of human disease to elucidate how PMN responses change in mono vs polymicrobial infections across host age and the role of CD73 in that, has the potential to uncover novel pathways that drive host susceptibly to infection. This work can lead to highly innovative approaches incorporating adenosine-based drugs to combat this serious lung disease.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2024	THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK	520 LEE ENTRANCE STE 211	AMHERST	NY	14228	ERIE	USA	Allergy and Infectious Diseases Research	000	2	5/6/2026	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $189,818 )
2024	2024	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	520 LEE ENTRANCE STE 211	AMHERST	NY	14228	ERIE	USA	Allergy and Infectious Diseases Research	000	2	12/29/2023	NON-COMPETING CONTINUATION	$170,835
2024	2024	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	520 LEE ENTRANCE STE 211	AMHERST	NY	14228	ERIE	USA	Allergy and Infectious Diseases Research	001	2	5/21/2024	NON-COMPETING CONTINUATION	$18,983
														Subtotal = $189,818

Issue Date FY: 2023 ( Subtotal = $229,575 )
2023	2023	RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK, THE	520 LEE ENTRANCE STE 211	AMHERST	NY	14228	ERIE	USA	Allergy and Infectious Diseases Research	000	1	2/24/2023	NEW	$229,575
														Subtotal = $229,575

Grand Total All Awards = $419,393

Top

All Categories

About

Search

Reports

Data Submission

Award Information

The role of PMNs and CD73 in host-resistance against S. pneumoniae / influenza A virus co-infection

Award Number: R21AI167956

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/24/2023

PERIOD OF PERFORMANCE END DATE: 01/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer